Small amounts of encephalom-ocarditis virus RNA direct a 50-fold increase in amino acid incorporation, in appropriately supplemented ascites tumor cell extracts, under conditions that give rise to authentic viral polypeptides. Incorporation in these crude extracts has a novel characteristic, namely, that it is almost entirely dependent upon the addition of exogenous tRNA. Further, this incorporation is restricted in that tRNA derived from ascites tumor cells or from rat liver permits translation of viral RNA, whereas tRNA from yeast or Escherichia coli does not. These translational barriers are due, at least in part, to an incompatibility between the tRNA of yeast and E. coli and the aminoacyl-tRNA synthetases of the ascites tumor cell. A more extensive basis for this incompatibility is suggested, however, by the failure of the E. coli aminoacyl-tRNA synthetases to restore viral RNA-directed protein synthesis in the presence of tRNA from E. coli, although the coli synthetases fully restore the poly(U)-directed synthesis of polyphenylalanine. The possible role that unique or favored codon classes might play in this restriction is considered, together with the implications of the observed requirement for tRNA.
RNA derived from the mammalian encephalomyocarditis virus directs protein synthesis in extracts of Krebs II ascites tumor cells from mice (1) (2) (3) (4) . The products of this reaction seem to correspond to authentic viral polypeptides (4, 5) and, in our studies, appear to be high molecular weight viral proteins, including structural elements of the virus (manuscript in preparation). This system, accurately translating viral RNA and, conceivably, other mammalian mRNAs, should prove extremely useful in examining translational mechanisms and their regulation in higher organisms. Indeed, this system has already been used to identify the initiating species of mammalian Met-tRNA (6) and in experiments designed to understand the mechanism of action of the antiviral agent, interferon (7) .
To establish this system in our own laboratory, we have adopted the procedures of Martin et al. (8) , of Kerr, Cohen, and Work (2) , and of Mathews and Korner (3) for the preparation of ascites tumor cell extracts. In addition, we have simplified the method used for the preparation of pure virus and improved its yield. Modifying this system in accord with the findings described below, we have considerably improved its activity with respect to the translation of viral RNA. It is now comparable in activity to systems derived from Escherichia coli (see ref. 9 ) and is clearly more efficient than other mammalian systems for the translation of an exogeneous natural mRNA (10) . The system also exhibits an 2303 interesting and apparently novel characteristic, namely, that the crude ascites tumor cell extract is almost entirely dependent upon the addition of tRNA. Moreover, this requirement is met by tRNA derived from mouse ascites tumor cells and from rat liver, but not by tRNA derived from yeast, a unicellular eukaryote, or from the prokaryote, E. coli. In this present work, we describe several details useful in the preparation of this system. We also demonstrate a tRNA requirement and the species specificity of this requirement and we delineate, in part, the basis of this specificity. Cells were propagated intraperitoneally by direct injection of 0.15 ml (containing about 5-10 X 107 cells/ml) of freshly harvested ascitic fluid (neither grossly bloody nor clotted) into 20-25 g NIH general purpose mice (Swisstar). Recourse was occasionally made to stored frozen cells for propagation, but these were always used after one passage, selecting the best fluid for further propagation. Special care was taken to harvest cells at about 7 days after injection. This procedure avoided the clotting seen in older fluid. The general procedures we have followed have been described by others (2, 3, 5, 8) .
All solutions were prepared with sterile water and all glassware was autoclaved. Cell extracts were prepared according to Mathews and Korner (3) . Fresh cells were washed three times by centrifugation (60 X g, 4 min) through cold buffer containing 35 mM Tris -HCl (pH 7.5)-140 mM NaCl. They were finally packed by centrifugation at 250 X g for 5 min, resuspended in 2 packed-cell volumes of buffer containing 10 mM Tris -HCl (pH 7.5)-10 mM KCl-1.5 mM Mg(CH8COO)2, and homogenized with about 20 strokes of a tightly fitting Dounce homogenizer. The homoge-nate was brought to a final concentration of 30 mM Tris -HC (pH 7.5)-125 mM KCl-5 mM Mg(CH3COO)2-7 mM 2-mercaptoethanol and centrifuged at 30,000 X g for 10 min. The pellet was discarded. After addition of 1 mM ATP, 0.1 mM GTP, 0.6 mM CTP, 10 mM creatine phosphate, 0.16 mg/ml of creatine kinase, and 40 MAM (each) of 20 amino acids, the extract was incubated at 370C for 45 min and centrifuged at 30,000 X g for 10 min. The supernatant solution was passed through a Sephadex G-25 column previously equilibrated with buffer containing 30 mM Tris HCl (pH 7.5)-120 mM KCl-5 mM Mg(CH3COO)2-7 mM 2-mercaptoethanol, or was dialyzed against the same buffer for 6 hr. Small aliquots were frozen and stored in liquid nitrogen. Little activity was lost if the material was quickly refrozen after use. Extracts used in these studies contained 10-14 mg/ml of protein, as measured by the method of Murphy and Kies (11) and had an A2a of 30-40 units/ml. The E. coli aminoacyl-tRNA synthetases were purified through the DEAE-cellulose step of Muench and Berg (12) .
tRNA was prepared by a modification of the procedure described by von Ehrenstein (13) . Fresh or frozen ascites tumor cells were washed as described above and finally suspended in 3 volumes of wash buffer. An equal volume of redistilled phenol saturated with buffer was added to the suspension. After they were shaken, the phases were separated, and the aqueous phase was saved. The phenol extraction was repeated, and the aqueous phases were pooled. 2 volumes of ethanol were added to the aqueous pool, and the resulting precipitate was collected by centrifugation and extracted twice with 1 M NaCl. The extracted material was again precipitated with 2 volumes of ethanol, collected, dissolved in 300 mM CH3COONa, pH 7.0, and the fraction precipitating between 0.54-0.98 volumes of isopropanol was collected. This material was dissolved in water, precipitated with 2 volumes of ethanol, washed twice in 2% CH3COOK (pH 5.5), containing 70% ethanol, and dissolved in water for use.
Preparation of virus and viral RNA Virus was grown on Krebs II ascites tumor cells, essentially as described by Burness (14) . Instead of swirling infected cell suspensions in flasks, bottles containing free magnetic stirrers were used. The volume of the medium was no greater than 10-15% of the container volume. After overnight incubation at 37°C, when the suspension is quite turbid, the cell suspension was chilled to 0-40C. Hemagglutination titers at this point were 1-2 X 104 HA units/ml. The solution was centrifuged at 10,000 X g for 10 min, made 0.2% in sodium acetate, and titrated to pH 5.0 with 2 N acetic acid. The resultant precipitate was collected by centrifugation at 10,000 X g for 10 min, and the virus was extracted by suspension in 1/50th of its original volume in a buffer containing 0.1 M NaCl-0.1 M potassium phosphate (pH 8.0)-0.2 M sodium pyrophosphate (14) . The virus could be further purified by the remaining steps of the Burness procedure. It was simpler for us, however, to use an alternative method. Concentrated virus was diluted 1:4 in sterile distilled water; 30 ml of this solution was layered over 5 ml of a CsCl solution having a density of 1.40 and centrifuged at 23,000 rpm for 3 hr at 10°C in a Spinco SW-27 rotor. The virus formed a band just beneath the CsCl-lysate interphase and was containing the virus were collected and pooled, and the density was adjusted to 1.33. The pooled virus was then centrifuged at 40,000 rpm at 10°C for 24 (3) . In a systematic effort to identify the necessary or the inactive component of the system, it was observed that, as isolated, the ascites tumor cell extract was almost entirely dependent upon the addition of tRNA (Fig. 1) . In this experiment, incorporation. This dependence is seen despite the fact that both ATP and CTP are present in reaction mixtures. The effect is also entirely dependent upon the addition of viral RNA, and the reaction is saturated by the addition of about 0.1 A26o unit of tRNA.
At saturating concentrations of tRNA, the system is extremely efficient in its ability to translate viral RNA (Fig. 2) . Less than 1 Mg of viral RNA directs a greater than 20-fold response in [8H]alanine incorporation and, at nearly saturating concentrations of viral RNA, the effect is more than 50 times the background value. Consistent with the previous studies (2, 3), we find that the Mg2+ concentration optimum for viral RNA-directed incorporation of [3H]alanine is quite low, in this case about 4 mM (Fig. 3) . In experiments not illustrated, we have also shown that viral RNA-directed incorporation proceeds at a linear rate for 1 hr, continues in a nonlinear fashion for another 1.5 hr, and, as would be expected of a mammalian system, is completely inhibited by cycloheximide, but is unaffected by chloramphenicol.
Specificity of the tRNA requirement
While there is considerable evidence that the genetic code is largely universal, it is also clear that degenerate codons and their respective tRNAs are represented to differing extents among various organisms (15) (16) (17) (18) . Similarly, there seems to be a limited range of species from which tRNAs can be derived to support protein synthesis in the ascites tumor cell system (Table 1, Expt. 1). tRNA derived from ascites tumor cells and from rat liver support viral RNA-directed incorporation of [3H]alanine. Incorporation in the presence of rat liver tRNA is somewhat less than that observed in the presence of ascite3 tumor cell tRNA, 7.05 pmol as compared to 5.80 pmol, but the difference is not great. In contrast, neither tRNA derived from yeast nor tRNA derived from E. coli permits significant amino acid incorporation. To determine whether the discrimination against the tRNA populations was due to the initiation reaction or whether it represented a more general incompatibility, poly(U)-directed polyphenyl- alanine synthesis was also tested ( If the basis for the observed tRNA specificity was exclusively the failure of specific aminoacyl-tRNA synthetases to charge heterologous tRNAs, this translational barrier might be overcome by the addition of aminoacyl-tRNA synthetases derived from the same species as the tRNA. We tested this possibility in the experiment shown in Table 1i Expt. 2 . An E. coli fraction containing partially purified aminoacyl-tRNA synthetases was added to the ascites tumor [Mg+2 ] mM 8 10 FIG cell system, and viral RNA-and poly(U)-directed protein synthesis was measured in the presence of tRNAE. .1j. Addition of the E. coli soluble fraction restored polyphenylalanine synthesis, but failed to restore viral RNA-directed protein synthesis. Therefore, the tRNA specificity involves, as a minimum, the inability of the ascites tumor cell aminoacyl-tRNA synthetases to charge certain nonhomologous tRNAs. This is shown directly for phenylalanine by the experiment illustrated in Table 2 , in which the ability of the ascites tumor extract to aminoacylate nonhomologous tRNAs was measured. It is clear that Phe-tRNAE. aUi was synthesized very poorly in the presence of ascites tumor cell extract, whereas this extract readily formed Phe-tRNA with tRNA derived from yeast and ascites tumor cells. This accounts for the ability of the ascites tumor cell extract to synthesize polyphenylalanine with tRNA from yeast, while requiring E. coli aminoacyl-tRNA synthetase with tRNA from E. coli (Table 1 ). In the case of alanine, in contrast, tRNA from ascites tumor cells and E. coli can be aminoacylated by the ascites tumor cell enzyme, but tRNAye..t cannot. The addition of the E. coli enzyme restored the amount of Ala-tRNA formed with tRNA from yeast. An incompatibility between the ascites tumor cell aminoacyl-tRNA synthetases and the tRNAs derived from yeast and E. coli could account for the inability of these tRNAs to support viral protein synthesis. However, it is also clear (see Table 1 ) that this deficiency was not corrected by the addition of an extract containing the requisite E. coli aminoacyl-tRNA synthetases*. Neither the nonhomologous tRNAs nor the E. coli aminoacyl-tRNA synthetases had a significant inhibitory effect upon viral RNA-directed protein synthesis in the system supplemented with tRNAamcites tumor cell (Table   3) . DISCUSSION Two of the major advantages of the viral RNA-ascites tumor cell system are that the virus can be grown to high titer in dense cell suspensions and that cells need not be maintained by delicate tissue culture procedures. There are additional advantages, however, which accrue when the system is supplemented with homologous tRNA, substantially improving its activity and permitting the synthesis of viral structural proteins of high molecular weight (manuscript in preparation) not seen in unsupplemented systems (see refs. 4 and 5) . This activity, in contrast to that seen i i the reticulocyte system (10), is fully dependent upon the addition of an exogenous mRNA. The tRNA dependence we observe has an additional significance. It permits a range of experiments using the 1500-2500 codons of the viral RNA to examine translational barriers involving tRNA, tRNA-dependent suppressor effects, and various regulatory models that implicate tRNA in translational control. These studies can be performed in a conveniently prepared system that responds to a natural mRNA and requires no specific manipulation to provide tRNA dependence.
In addition to these more practical implications, a question arises as to why, of the many macromolecular components * (27) -that the concentrations of tRNA in these mammalian cells fluctuate independently of the other elements involved in translation and that they are regulated by demands on the protein synthetic apparatus. Certainly alterations in specific tRNAs have been observed as a function of variation in growth conditions (see an extensive bibliography in ref. 28) .
The incompatibility between tRNA derived from unicellular organisms and mammalian extracts that we observe is, at least in part, due to an inability of the ascites tumor cell aminoacyl-tRNA synthetases to charge certain E. coli and yeast tRNAs. Incompatibility between the tRNA of one source and an aminoacyl-tRNA synthetase of another has been observed among several species (29) (30) (31) (32) (33) (34) (35) . However, our data suggest that this restriction may have a more extensive basis, possibly involving the favored use of specific degenerate codon classes by the virus and the ascites tumor cell. Such barriers may extend to less closely related higher organisms, to specialized organs of a single species, to organs at various stages of development, or even to certain viruses and their hosts. The viral RNA-ascites tumor cell system, coupled with careful product analysis, should be especially sensitive in their detection.
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